Under the agreement, PharmAthene has acquired all of the assets related exclusively to Avecia’s vaccines business, including the intellectual property rights associated with its recombinant Protective Antigen (rPA)
The objective of the dose-escalation trial is to determine the maximum tolerated dose of MKC-1 administered orally twice a day continuously in advanced or refractory solid tumor patients.
The trial is a randomized, open-label, prospective, multicenter study that will compare the safety and efficacy of three different Coroxane dosing schedules to primary percutaneous balloon angioplasty with
Panflu is claimed to be the first and only approved vaccine available in China against the H5N1 influenza virus. The vaccine is approved for production solely to be
The orphan drug designation encompasses all subsets of multiple myeloma and Waldenstrom’s macroglobulinemia. The orphan drug act provides the drug developer with several financial benefits and incentives related
The agreement provides for the two companies to collaborate on the development of certain orthopaedic soft tissue repair applications for which Tornier will distribute the product to its
This announcement is made following an agreement between Joe Thomas, managing member of Inpulse Phoenix and VitalCare, for 100% of Inpulse Phoenix’s interest in the Scottsdale, Arizona diabetes
The objectives of this study are to evaluate the safety of multiple doses of EVP-6124 in this patient population, to investigate potential drug-drug interactions, and to determine the
Alpha-1 Antitrypsin (AAT) is used to treat hereditary AAT deficiency which leads to Congenital Emphysema. David Tsur, CEO of Kamada, said: “The company’s intravenous Alpha-1 Antitrypsin (AAT) is
The Phase II dose-finding study is designed to further evaluate the ability of BA058 to build new bone for the treatment of osteoporosis in postmenopausal women. The randomized,
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.